Completed PHASE3 INTERVENTIONAL 2-arm NCT01384903

An Open-label Study of KW-3357 (3357-004)

An Open-label Study of KW-3357 Compared to Plasma-derived Antithrombin for Disseminated Intravascular Coagulation (DIC) Associated With Infection

Sponsor: Kyowa Kirin Co., Ltd.

Conditions Disseminated Intravascular Coagulation (DIC)

Interventions KW-3357 Plasma-derived antithrombin

Updated 8 times since 2017 Last updated: Mar 22, 2017 Started: Jun 30, 2011 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Disseminated Intravascular Coagulation (DIC), this trial is completed. The trial is conducted by Kyowa Kirin Co., Ltd. and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Aug 2019 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Apr 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kyowa Kirin Co., Ltd.

Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saga, Japan